Clinical trials: Objective Response Rate
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic…
- Trial name
- KEYNOTE-B84 (NCT04815720)
- Testing
- pepinemab + pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vaccinex Inc.
Breast Cancer
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
The purpose of the study was to determine whether treatment with a PI3K inhibitor plus letrozole led to an increase in pathologic clinical response and Objective Response Rate compared to treatment with placebo plus letrozole in…
- Trial name
- NCT01923168
- Testing
- alpelisib, buparlisib
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 340 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Hepatocellular
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
This is a study to investigate the potential clinical benefit of refametinib when given in combination with sorafenib as first line treatment in patients with unresectable or metastatic HCC carrying a RAS mutation.
- Trial name
- NCT01915602
- Testing
- Refametinib (BAY86-9766), Sorafenib (BAY43-9006)
- Where
- 79 sites in United States, Austria and 19 more
- Volunteers
- 14 people
- Sponsor
- Bayer
Breast Cancer
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
The purpose of this study is to determine the efficacy and tolerance of the association of two drugs already marketed and used to treat your disease: Arimidex® 1 Mg per day per os and Zoladex® 3,6 Mg in injections under cutaneous…
- Trial name
- NCT00235937
- Testing
- Anastrozole and goserelin
- Where
- 7 sites in France
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Dose Escalation, Safety
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies.
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors
- Trial name
- NCT01576666
- Testing
- LDE225, BKM120
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed and Refractory Multiple Myeloma (RRMM)
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Primary Objective: 1. To describe the distribution of treatment regimens and objective response rate (ORR) in a Benchmark Cohort of real-world patients with relapsed/refractory multiple myeloma (RRMM) who initiate treatment after…
- Trial name
- NCT05673967
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer, Melanoma
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
This was a single-arm, open-label, multi-center, Phase II study to evaluate dabrafenib and trametinib combination therapy in subjects with BRAF V600 mutation-positive, unresectable or metastatic Acral lentiginous or cutaneous…
- Trial name
- NCT02083354
- Testing
- Dabrafenib, Trametinib
- Where
- 13 sites in China, Hong Kong and 3 more
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms
To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent
To determine the Objective Response Rate of 4 cycles of docetaxel + anthracycline (epirubicin or doxorubicine) followed by 4 cycles of docetaxel single agent.
- Trial name
- NCT00620100
- Testing
- Docetaxel
- Where
- 2 sites in Austria, Poland
- Volunteers
- 2 people
- Sponsor
- Sanofi
Follicular Lymphoma
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
This study aims to evaluate how well the effectiveness of the medicine Tazemetostat works in adults with relapsed/refractory follicular lymphoma, a slow-growing type of blood cancer that affects a kind of white blood cell called…
- Trial name
- NCT07282548
- Sponsor
- Ipsen
Carcinoma, Hepatocellular
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
This is a study to investigate the potential clinical benefit of refametinib in patients with unresectable or metastatic HCC carrying a RAS mutation. The study will be conducted in 2 stages.
- Trial name
- NCT01915589
- Testing
- Refametinib (BAY86-9766)
- Where
- 58 sites in United States, Austria and 15 more
- Volunteers
- 16 people
- Sponsor
- Bayer
Colorectal Cancer
A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
The multicenter, open-label, single-arm, non-randomized, two-stage Simon's design, phase II study (The CLMO-001 Trial) will evaluate the efficacy and safety of bevacizumab in combination with mFOLFOX-6 (Levofolinic acid…
- Trial name
- NCT01383707
- Testing
- 5-Fluorouracil (5-FU), Bevacizumab, Levofolinic acid
- Where
- 11 sites in Italy
- Volunteers
- 77 people
- Sponsor
- Hoffmann-La Roche
GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
The purpose of this study is to determine whether GSK1120212, a MEK inhibitor, is an effective and safe treatment for cancer subjects with metastatic uveal melanoma and mutation-positive GNAQ or GNA11 metastatic melanoma.
- Conditions
- GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma, Cancer, Metastatic Uveal Melanoma
- Trial name
- NCT01328106
- Testing
- GSK1120212
- Sponsor
- GlaxoSmithKline
Overactive Bladder
Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.
Measuring sympathetic skin response or heart rate variability can provide an objective biomarker of bladder sensation and its modulation by drug with potential to treat overactive bladder.
- Trial name
- NCT00481728
- Testing
- Tolterodine, Filling cystometry, Intravesical neurostimulation
- Where
- Switzerland
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cancer
Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor
MEK113583 is a Phase II open-label, multi-site study to investigate the objective response rate, safety, and pharmacokinetics of GSK1120212 in subjects with BRAF mutation-positive melanoma who were previously treated with or…
- Trial name
- NCT01037127
- Testing
- GSK1120212
- Where
- 10 sites in United States, Australia
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Metastatic Castration-resistant Prostate Cancer
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor…
- Trial name
- NCT06520345
- Testing
- 177Lu-TLX591, Enzalutamide, Abiraterone
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 520 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Unresected Stage IIIb to IVM1c Melanoma
Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
The study is a phase 2, multi centered, single arm study designed to evaluate the correlation between cluster of differentiation 8-positive (CD8+) cell density and objective response rate in adults with unresected stage IIIB to…
- Trial name
- TVEC-325 (NCT02366195)
- Testing
- Talimogene Laherparepvec
- Where
- 42 sites in United States, Austria and 11 more
- Volunteers
- 112 people
- Sponsor
- Amgen